Research Associate-Sr Assoc, Oncology

Job Description
Regulus Therapeutics Inc. (NASDAQ:RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus is uniquely positioned to leverage a mature therapeutic platform that harnesses the oligonucleotide drug discovery and development expertise of Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc., which founded the company. Regulus has a well-balanced microRNA therapeutic pipeline entering clinical development, an emerging microRNA biomarkers platform to support its therapeutic programs, and a rich intellectual property estate to retain its leadership in the microRNA field. Regulus’ intends to focus its proprietary efforts on developing microRNA therapeutics for oncology indications and orphan diseases and is currently advancing several programs toward clinical development in oncology, fibrosis and metabolic diseases. Our first clinical candidate, RG-101, targets microRNA-122 for the treatment of patients with chronic hepatitis C virus infection, or HCV. We filed our first application for RG-101 with regulatory authorities in the Netherlands and recently received approval to commence a Phase I clinical trial. Additionally, we nominated RG-012, an anti-miR targeting miR-21 for the treatment of Alport Syndrome, an orphan, life-threatening kidney disease driven by genetic mutations, as our second microRNA candidate for clinical development. In January 2014, we expanded our biomarkers efforts and established microMarkers™, a research and development division focused on identifying microRNAs as biomarkers of human disease, which is designed to support our therapeutic pipeline, collaborators and strategic partners. Regulus’ commitment to innovation and its leadership in the microRNA field have enabled the formation of strategic alliances with AstraZeneca, GlaxoSmithKline and Sanofi and a research- collaboration with Biogen Idec.

Regulus is located in La Jolla, California and is led by a seasoned executive team experienced in corporate management, business, science, drug discovery and development. Regulus’ scientific advisory board consists of world-class scientists and some of the foremost authorities in the field of microRNA research. In 2014, Regulus has outlined a strategy, named the ‘Clinical Map Initiative’, which outlines certain corporate goals and objectives to advance our microRNA therapeutics pipeline over the next several years. Specifically, we intend to demonstrate human proof-of-concept results in the Phase I clinical study of RG-101 by the end of 2014, initiate a Phase I clinical study of RG-012 for the treatment of Alport Syndrome in the first half of 2015 and nominate a third microRNA candidate for clinical development by the end of 2014, enabling us to have at least two, potentially three, clinical programs established by 2015. In order to achieve these objectives, we intend to maintain a strong financial position and end 2014 with approximately $75 million in cash, cash equivalents and short-term investments.

We are currently seeking a highly motivated Research Associate/Senior Research Associate in Oncology to be part of a unique and exciting opportunity in drug discovery. For more information, visit www.RegulusRx.com.

Research Associate/Senior Research Associate Oncology – 452

Regulus seeks an experienced Research Associate with 5-10 years of experience, to join a microRNA therapeutic development team focused on oncology. The position requires a true understanding of disciplined drug discovery, supporting programs moving towards clinical candidate development. Industrial experience is required along with experience working in a matrix environment. Required qualifications include hands-on experience conducting and managing in vitro studies requiring design, development of in vitro cell-based plate assays for drug discovery cascades, in-depth experience with FACs analysis, cell cycle and apoptosis assays, colony formation assays, Western blot analysis, ELISAs and other common Oncology assays. Experience with in vivo xenograft and/or transgenic models are desirable. Utilizing non-invasive optical imaging (i.e. IVIS/Xenogen) is a plus.

All highly motivated applicants interested in exploring microRNA biology and function and developing novel therapeutics are encouraged to apply.

Requirements:
?BS/MS in Cell Biology or Molecular Biology or related discipline
?5-10 years hands on experience conducting in vitro Oncology studies. Industrial experience is required (a minimum of 5 years)
?Broad knowledge and expertise in Oncology including cell signaling, cell cycle and apoptotic pathways
?Attention to detail, proficient reasoning skills in experimental design, data analysis, statistical methods and interpretation is a must.
?Excellent written and oral communication skills
?Independence, problem-solving abilities, self-motivation, resourcefulness and the ability to work in a fast paced team environment are essential.

Company

Regulus Therapeutics

Job Code

State or Province

California

Apply
 Print  Close
Terms and Conditions I ©2000-2024 Candidate Seeker, Inc. I ©1994-2024 Brolin Corporation
   Powered by Portal Prodigy